Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.
Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Vigil Neuroscience. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.
Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and Dana Farber’s Binney Street Capital advisory board. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.
Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.
What is Bruce Booth's net worth?
The estimated net worth of Bruce Booth is at least $48.00 million as of June 29th, 2026. Dr. Booth owns 461,794 shares of Kymera Therapeutics stock worth more than $48,003,486 as of August 4th. This net worth evaluation does not reflect any other assets that Dr. Booth may own. Learn More about Bruce Booth's net worth.
How do I contact Bruce Booth?
Has Bruce Booth been buying or selling shares of Kymera Therapeutics?
Bruce Booth has not been actively trading shares of Kymera Therapeutics within the last three months. Most recently, Bruce Booth sold 31,283 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $109.48, for a transaction totalling $3,424,862.84. Following the completion of the sale, the director now directly owns 461,794 shares of the company's stock, valued at $50,557,207.12. Learn More on Bruce Booth's trading history.
Who are Kymera Therapeutics' active insiders?
Are insiders buying or selling shares of Kymera Therapeutics?
In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 2,005,813 shares worth more than $172,499,918.00. In the last twelve months, insiders at the sold shares 63 times. They sold a total of 4,616,352 shares worth more than $469,192,904.98. The most recent insider tranaction occured on July, 7th when CEO Nello Mainolfi sold 50,000 shares worth more than $5,950,000.00. Insiders at Kymera Therapeutics own 16.0% of the company.
Learn More about insider trades at Kymera Therapeutics. Information on this page was last updated on 7/7/2026.
